• Applied MTT Use-Cases: Optimizing Cell Proliferation Assays

  2026-05-28

  MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) enables precise, high-sensitivity colorimetric cell viability and metabolic activity measurements across diverse in vitro models. This article translates cutting-edge research and expert workflows into actionable, troubleshooting-rich protocols, ensuring robust and reproducible results for cell-based assays.

• ECM1 from Osteoblasts Drives Anti-Androgen Resistance in Pro

  2026-05-28

  This study uncovers how osteoblast-derived ECM1 protein promotes resistance to enzalutamide in bone metastatic prostate cancer through ENO1-mediated MAPK signaling activation. The findings highlight the tumor microenvironment's pivotal role in therapy resistance and suggest novel targets for overcoming castration-resistant disease.

• Liproxstatin-1 HCl: Advancing Ferroptosis Assays for Transla

  2026-05-27

  Explore how Liproxstatin-1 HCl transforms ferroptosis research, with new mechanistic insights into mitochondrial calcium signaling, actionable protocol guidance, and strategic perspectives for translational scientists tackling acute organ injury models.

• Phosphatase Inhibitor Cocktail 1 (100X in DMSO): Protocol Gu

  2026-05-27

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) addresses the challenge of preserving protein phosphorylation during sample preparation by inhibiting alkaline and serine/threonine phosphatases. This product is suited for applications such as Western blotting, phosphoproteomic analysis, and kinase assays, but is not intended for diagnostic or clinical use. It is essential to use the cocktail as directed to prevent dephosphorylation artifacts in basic research workflows.

• SCUBE3 Antibody Targeting Suppresses Oncogenic Signaling and

  2026-05-26

  The reference study identifies secreted SCUBE3 as a multifunctional driver of tumor growth, therapy resistance, and immunosuppression. Antibody-mediated targeting of SCUBE3 disrupts oncogenic signaling and restores antitumor immunity, offering a promising pan-cancer therapeutic strategy with translational relevance for researchers studying EGFR and related pathways.

• Catalpol in Translational Disease Models: Advanced Protocols

  2026-05-26

  Catalpol unlocks multi-pathway modulation for neuroprotection and disease modeling, offering both mechanistic versatility and protocol precision. Its validated inhibition of NF-κB and activation of TrkB pathways enables robust cognitive rescue in LPS-induced models, with reproducible dosing and workflow strategies for translational research.

• 2-Hydroxypropyl-β-cyclodextrin: Solubility Protocol and Limi

  2026-05-25

  2-Hydroxypropyl-β-cyclodextrin enhances the aqueous solubility of poorly water-soluble, hydrophobic compounds, particularly those containing aromatic or phenyl groups, by forming inclusion complexes. It is suitable for use as a drug formulation excipient in pharmaceutical and biochemical research workflows focused on solubility improvement. Broader or therapeutic uses are not supported by current product documentation.

• GANT61 and GLI2: Unraveling Immune Evasion in Cancer Models

  2026-05-25

  Explore how GANT61, a selective GLI inhibitor, uniquely dissects the role of GLI2 in tumor immune evasion and guides advanced cancer research workflows. This article reveals mechanistic insights and practical assay strategies not covered by standard protocol guides.

• D-Luciferin: Enhancing Bioluminescent Imaging in Tumor Immun

  2026-05-24

  D-Luciferin empowers precise, non-invasive monitoring of tumor progression and immune cell dynamics in living models, elevating both experimental rigor and translational impact. Its high-affinity firefly luciferase substrate chemistry makes it indispensable for ATP quantification and real-time gene expression assays across oncology and immunotherapy research.

• CCG-1423: Precision RhoA Inhibitor Workflows in Cancer and V

  2026-05-23

  CCG-1423 empowers researchers to dissect RhoA/ROCK signaling with unprecedented specificity, enabling high-resolution analysis of cancer cell invasion and viral pathogenesis. Its unique inhibition of MRTF-A/importin α/β1 unlocks new avenues for apoptosis assays and tight junction studies, making it an essential tool in translational research.

• Genistein in Cytoskeleton-Dependent Autophagy Assays

  2026-05-22

  Genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one) is a selective tyrosine kinase inhibitor that empowers high-precision studies of autophagy and cancer chemoprevention. This guide details protocol enhancements, troubleshooting, and advanced workflow design for leveraging Genistein in cytoskeleton-dependent cell-based assays, informed by the latest mechanistic and experimental insights.

• Dacarbazine: Applied Protocols for Oncology Research Success

  2026-05-22

  Dacarbazine stands out as a gold-standard antineoplastic chemotherapy drug, enabling high-fidelity modeling of cancer DNA damage pathways in malignant melanoma, Hodgkin lymphoma, and sarcoma. This article delivers actionable workflows, expert troubleshooting, and reference-backed optimization tips to maximize experimental reproducibility and translational impact.

• ICOS Signaling Drives Th2 Differentiation in Allergic Rhinit

  2026-05-21

  This study identifies inducible co-stimulator (ICOS) signaling as a central regulator of T cell subset differentiation, particularly Th2 cells, in allergic rhinitis (AR). The findings reveal ICOS-expressing Th2 cells as potential therapeutic targets and clarify how PI3K-Akt-mTOR pathway modulation impacts immune responses in AR.

• Caspofungin: Advanced Insights for β-(1,3)-D-Glucan Inhibiti

  2026-05-21

  Explore how Caspofungin, a lipopeptide antifungal drug, empowers innovative research into fungal cell wall biosynthesis inhibition. This article delivers a technical deep dive into assay design, resistance management, and practical workflow optimization, uniquely extending beyond existing resources.

• LY2603618 Chk1 Inhibitor: Applied Workflows & Troubleshootin

  2026-05-20

  LY2603618 stands out as a highly selective Chk1 inhibitor, enabling precise modulation of the DNA damage response and enhancing cancer chemotherapy sensitization. This guide details validated protocols, advanced use-cases, and expert troubleshooting to maximize reproducibility and performance in oncology research.

15758 records 2/1051 page Previous Next 12345 下5页 Last page